Drug Profile

Second generation recombinant interleukin-2 - 3SBio

Alternative Names: NuLeusin

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 3SBio
Class Antiallergics; Antihyperglycaemics; Antineoplastics; Immunotherapies; Interleukins; Mood stabilisers; Recombinant proteins
Mechanism of Action Interleukin 2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Suspended Malignant melanoma; Renal cancer

Most Recent Events

10 Nov 2011 3SBio suspends its support for additional clinical trials of NuLeusin^® after China's SFDA requested further trials in a larger patient population
17 May 2010 Preregistration for Malignant melanoma in China (SC)
10 Nov 2008 Preregistration for Renal cancer in China (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com